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Abstract 
In a consanguineous Pakistani family with 2 affected individuals, a homozygous variant 
Gly399Val in the 8th transmembrane domain of the taurine transporter SLC6A6 was identified 
resulting in a hypomorph transporting capacity of ~15% compared to normal. 3D modeling of this 
variant has indicated that it likely causes displacement of the Tyr138 (TM3) side chain, important 
for transport of taurine. The affected individuals presented with rapidly progressive childhood 
retinal degeneration, cardiomyopathy, and almost undetectable plasma taurine levels. Oral taurine 
supplementation of 100mg/kg/day resulted in maintenance of normal blood taurine levels. 
Following approval by the ethics committee, a long-term supplementation treatment was 
introduced. Remarkably, after 24-months, the cardiomyopathy was corrected in both affected 
siblings, and in the 6 y.o. the retinal degeneration was arrested, and the vision was clinically 
improved. Similar therapeutic approaches could be employed in mendelian phenotypes caused by 
the dysfunction of the hundreds of other molecular transporters.  
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Introduction  
Transporters constitute a large number of cell membrane proteins involved in the uptake of small 
molecules into cells(1). The current human gene catalogue contains 423 protein-coding genes 
classified as solute carrier (SLC)(1) (https://www.genenames.org/data/genegroup/#!/group/752). 
Members of this large gene family are involved in a number of human disorders; OMIM contains 
268 entries with dominant, recessive, and X-linked mendelian phenotypes caused by pathogenic 
variants in these genes (24sep19 search https://www.omim.org/).  
Genome or exome sequencing provided the opportunity to identify novel causative links between 
pathogenic variants of genes and mendelian phenotypes. This is particularly important for the 
discovery of novel autosomal recessive genes since the majority of those are still unknown. 
Consanguinity, which is practiced in a considerable fraction of world’s populations, provides a 
means to identify novel recessive genes because of the large genomic regions of homozygosity in 
the offspring of closely related parents(2). The identification of pathogenic variants in novel genes 
causing recessive disorders provide a better understanding of the molecular pathophysiology of 
the resulting phenotype, and the opportunity for improved diagnostic services to the affected 
families and populations; occasionally, new therapeutic options could be offered based on the 
underlying molecular mechanism.  
As part of the Swiss-Pakistani consanguinity project, to identify novel genes for visual impairment 
or intellectual disability(3, 4), we present a novel gene for childhood progressive retinal 
degeneration and cardiomyopathy in one family. The taurine transport defect identified due to a 
hypomorph homozygous pathogenic variant in the SLC6A6 gene, has provided the opportunity 
for treatment with long-term taurine supplementation. After 24 months of treatment the 
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cardiomyopathy was corrected in both affected siblings, and in the 6 y.o. the retinal degeneration 
was arrested and the vision was clinically improved. 
  





We used exome sequencing and genotyping of more than 200 Pakistani consanguineous families 
with multiple affected individuals to identify candidate genes and high impact variants responsible 
for recessive visual impairment. In one of these consanguineous families, F315, from the Kohat 
region of Pakistan with 2 affected individuals, we have identified a homozygous deleterious 
variant Gly399Val (NM_003043.5:c.1196G>T) in the taurine transporter SLC6A6 (MIM:186854) 
that segregated with the phenotype of progressive retinal degeneration (Figure 1A, 1B). Gly399 of 
SLC6A6 is well-conserved in all vertebrates (Figure 1C), and 3D molecular modeling (Figure 1D) 
predicted that the Val399 substitution causes a displacement of Tyr138 side chain, important for 
the recognition and transport of the ligand. Blood taurine levels in the two affected individuals 
IV:1 and IV:3 were almost undetected (6-7 μmol/l).  
Functional analysis 
 
Transient and stable transfection of the Gly399Val variant in HEK-293 cells resulted in a 
hypomorph with transport capacity of ~15% compared to normal as determined by single point 
(Figure S2) and saturation (Figure S3 and Table S6) radioactive taurine uptake analyses. 
Fibroblasts from affected and carrier individuals of the family showed similar results where single 
point uptake revealed significant taurine uptake deficits in the affected individuals compared to 
carriers (Figure S4) consistent with kinetic data showing a significant reduction in VMAX  (Figure 
2A and Table S7). Plasma membrane expression analysis in HEK-293 cells and fibroblasts 
strongly support that the transport deficit is functional rather than a result of decreased surface 
protein (Figure S5 and Figure 2 panels B and C). In HEK-293 cells, taurine transport KM values 
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were 3.4-fold lower in SLC6A6 Gly399Val compared to the normal transporter (Table S5) and 
whereas this could contribute to decreased transport capacity in HEK cells, KM values were 
unchanged between affected and carrier fibroblasts (Table S7) indicating the reduced taurine 




Clinical examinations in the University Hospitals of Geneva revealed a cone-rod retinopathy and 
cardiomyopathy. The older 15 y.o. male IV:1 had light perception vision due to advanced macular 
atrophy with severe peripheral alterations including pseudoosteoblast formation and peripheral 
atrophy. There was no retinal response in the electroretinogram (ERG) and extensive loss of 
photoreceptors was noted in the optical coherence tomography (OCT). The younger 6 y.o. female 
IV:3 had vision of counting fingers due to foveal-spearing macular atrophy. There were less 
marked peripheral retinal changes (salt-and-pepper fundus pigmentation), no response in global 
ERG, and minimal electrical focal macular response in the multifocal ERG. The OCT showed 
atrophy of the photoreceptors with persistence of residual photoreceptors in the central area (Figure 
S1). Echocardiography showed mild hypokinetic cardiomyopathy in both affected individuals with 
systolic dysfunction (shortening fraction 24-27%) and systolic dilatation of the left ventricle 
(Figure 3B); the effort test was however within normal limits. In both patients, brain MRI and 
hepatic ultrasound was normal (Table S1). Plasma amino acids showed very low levels of taurine 
in the affecteds and intermediate levels in the carrier parents (Figure 3A).  
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Taurine supplementation treatment 
The oral taurine loading test and subsequent supplementation at 100mg/kg/day resulted in 
maintenance of normal blood taurine levels in both affected individuals (more than 40 μmol/l in 
each patient) (Figure S6, Figure 3A).  We hypothesized that taurine administration may be 
beneficial in this family. Following approval by the ethics committee of the University Hospitals 
of Geneva (protocol #CER 11-036), a long-term oral supplementation treatment of 100mg/kg/day 
taurine divided in 3 doses was introduced upon return of the family to Pakistan. Remarkably, after 
24 months of treatment, the cardiomyopathy was corrected in both affected siblings. The heart 
function objectified by echocardiography measurements were within normal limits; indicatively, 
the fractional shortening of the left ventricle in both affected children was 32% (normal range of 
30-40%) (Figure 3B). In the female IV:3 (now 8 y.o.) we have noted an improved visual 
performance with the visual acuity of 20/100 in the right eye and 20/160 in the left eye, while the 
ophthalmological exams showed stability of the anatomy of the central retina, suggesting an arrest 
in the further degeneration of the retina (Figure 1C, 1D). Note that the elder brother (IV:1) had a 
complete visual loss at the age of 8-years. No side effects from the taurine supplementation were 
noted, as previously reported(5). 
  




Taurine is the most abundant amino acid in the retina, important in photoreceptor survival and 
protection from oxidative stress and light damage(6, 7). Mice with targeted disruption of the 
Taut/Slc6a6 gene develop degenerative retinal disease(8) similar to that observed in the family 
F315. Furthermore, chemically-induced taurine deficiency in mice following a treatment with a 
taurine transporter inhibitor guanidoethane sulfonate, resulted in photoreceptor degeneration and 
retinal ganglion cell loss(7, 9, 10). In addition, taurine deficiency in cats and dogs(11) causes 
cardiomyopathy(12). Dogs diagnosed with taurine deficiency and dilated cardiomyopathy had 
significant improvement in their echocardiographic parameters and normalization of taurine 
concentrations following diet change and taurine supplementation(11). 
 In this study we present a family with taurine deficiency due to a homozygous amino acid 
substitution in third transmembrane domain (TM3) of the taurine transporter SLC6A6. The 
identification of the functional defect of the taurine transporter SLC6A6 in this consanguineous 
family which altered taurine homeostasis provided an opportunity for treatment. Two years of oral 
taurine supplementation resulted in complete reversal of the systolic cardiomyopathy in both 
affected children, and non-progression of the retinopathy in the younger sibling. We propose the 
continuation of the taurine supplementation with the objective to stabilize the retinal damage. 
Additional families with this novel SLC6A6 retinopathy and cardiomyopathy are necessary to 
establish the therapeutic value of oral taurine supplementation. This study emphasizes the 
contribution of each novel mendelian gene in the understanding of disease etiology, and provides 
the opportunity to investigate nutritional or pharmaceutical therapy for severe mendelian disorders 
due to the large family of 423 transporter-encoding genes(1). In addition, the identification of 
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novel genes for autosomal recessive disorders provides the opportunity for carrier detection in the 
extended pedigree and family planning. 
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Materials and Methods 
 
Family ascertainment 
Family (F315) was ascertained and sampled by the Institute of Basic Medical Sciences (IBMS), 
Khyber Medical University, Peshawar, Pakistan and was studied at the Department of Genetic 
Medicine and Development, University of Geneva, Switzerland. The study was approved by the 
ethical committee of the Khyber Medical University, Peshawar, Pakistan and by the Bioethics 
Committee of the University Hospitals of Geneva (Protocol number: CER 11-036). Informed 
consent was signed by the guardians of this family. Blood samples were obtained from all 
individuals of the family including affecteds, unaffected siblings and both parents. Genomic DNA 
was extracted from blood samples. 
  
Genetic analysis 
Exome sequencing of the proband (IV:3) was performed as described previously(13). All the 
family members including affecteds (IV:1 and IV:3), unaffected siblings (IV:4 and IV:5) and both 
parents (III:3 and III:4) were genotyped to identify the runs of homozygosity (ROH). Screening of 
all the ROHs segregating with the disease phenotype, identifying variants from the exome 
sequencing present in the segregating ROHs, and filtering of the selected variants were performed 
by using CATCH(14). Filtering and prioritization of likely pathogenic variants was performed as 
described previously(4, 13). All candidate variants were validated by Sanger sequencing (Figure 
1B). 
  
 [3H Taurine] Uptake Assay and Surface Biotinylation 
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Human embryonic kidney (HEK-293) cell lines were transfected with standard TransIT-LT1 
protocol to stably express either wildtype taurine transporter SLC6A6 (formerly called TauT) or a 
SLC6A6 containing the SNP Glu399Val. HEK-293 cells transiently transfected or stably 
expressing SLC6A6 or the Glu399Val mutation (100,000 cells/well) or primary fibroblasts 
(50,000 cells/well) were plated in a 24 well culture plate (culturplate-24, Perkin-Elmer, Inc) and 
grown for 24 h. Single point uptake of 30 nM or 5 µM [3H] taurine (Perkin Elmer) with vehicle 
or indicated concentrations of cold taurine was carried out for 10 minutes at 37˚C. 5 µM was 
obtained by mixing [3H] taurine with non-labeled taurine. Uptake was terminated with three 
washes of ice-cold KR buffer of pH 7.4. Radioactivity remaining in cells was measured by liquid 
scintillation. Non-specific uptake was determined for HEK-293 cells by subtracting radioactivity 
obtained with parental, non-transfected cells. Non-specific uptake for primary fibroblasts was 
determined by uptake in the presence of 25 mM non-labeled β-alanine. For saturation analysis, 
[3H] taurine was diluted into non-labeled taurine to obtain the necessary concentrations. Statistical 
significance was determined using unpaired T-Test and one-way ANOVA (post-Tukey Test) with 
significance set at p < 0.05. 
The protocol for surface biotinylation is described in the supplementary data. SLC6A6 expression 
was normalized to TFRC for each sample.  
 
Taurine loading test and supplementation 
A taurine loading test was performed in the Pediatrics clinical research unit of the University 
hospitals of Geneva after approval by the ethics committee. We have administered an oral bolus 
dose of 100mg/kg of Taurine to the two affected individuals and their heterozygous parents on day 
2, as this dose was recommended by the literature as non-toxic(5). Taurine was provided in tablets, 
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commercialized by Burgerstein Pharmaceuticals. Repeated measurements of taurine in blood and 
urine were subsequently performed. On days 3 and 4, the patients received a 100mg/kg/day, 
administered in 3 doses (33mg/kg/q8hours). 
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Figure1. The segregation, conservation and 3D modeling of the SLC6A6 pathogenic variant 
Gly399Val in family F315 (A) Pedigree of consanguineous family F315 showing the segregation 
of the homozygous pathogenic variant NM_003043.5:c.1196G>T:p.(Gly399Val) in the SLC6A6 
gene. (B) Chromatograms of Sanger sequencing showing the segregation of the SLC6A6 variant 
c.1196G>T:p.(Gly399Val) in all family members tested. (C) Amino acid alignment in various 
species showing that Gly399 is well conserved. (D) Molecular modeling of the SLC6A6 variant 
Gly399Val indicating that Val399 is predicted to cause the displacement of the Tyr138 (TM3) side 
chain, which is important for recognition and transport of the ligand.  
Figure2. Functional characterization of SLC6A6 activity from patient-derived fibroblasts. 
(A) Specific Taurine Saturation Uptake Analysis in Patient-derived Fibroblasts. Fibroblasts of 
affected individuals IV:1 (filled circle), IV:3(open circle),  and parents III:3 (closed square) and 
III:4 (open square) were incubated with [3H] taurine concentrations from 0.05 to 250 µM for 10 
min. Non-specific counts were determined by inhibition of SLC6A6 with β-alanine (25 mM) and 
subtracted from total counts. (B) Western Blot detection of SLC6A6 in the plasma membrane from 
patient-derived fibroblasts. Surface protein was purified through biotinylation with a cell 
impermeant crosslinker and detected using anti-SLC6A6 antibody. (C) Percent surface expression 
was calculated from band densitometry for each sample and normalized to TFRC and plotted. * 
P<0.05 
Figure3. Results of taurine supplementation therapy for 24-months (A) Taurine levels in the 
blood of both affected individuals (IV:1 and IV:3) before and after 6-months, 1-year and 2-years 
of taurine supplementation. (B) Results of the echocardiography show that the cardiomyopathy of 
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both affected individuals (IV:1 and IV:3) has been corrected after 2-years of taurine 
supplementation. LVESD: left ventricular end-systolic diameter, LVEDD: left ventricular end 
diastolic diameter, EF: ejection fraction, FS: fractional shortening. Green and red numbers 
represent normal and abnormal values respectively. (C, D) Fundus photographs and macular OCT 
of the right eye (C) and left eye (D) of the patient IV:3 at baseline and after 24 months of taurine 
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The initial analysis was done by performing the exome sequencing of the proband (IV:3) by using 
SureSelect Human All Exon v6 reagents (Agilent Technologies, Santa Clara, CA, USA). The 
sequencing was performed on an Illumina HiSeq4000 platform. A customized pipeline was used 
to analyze the exome sequencing data, that includes the published algorithms,  Burrows-Wheeler 
aligner tool (BWA)(1), SAMtools(1), PICARD and the Genome Analysis Toolkit (GATK)(2), and the 
sequenced reads were aligned to the GRCh37/hg19(3) reference human genome. The filtering 
and interpretation of the filtered variants was performed as described in previous studies(4, 5).  
All the family members including affecteds (IV:1 and IV:3), unaffected siblings (IV:4 and IV:5) and 
both parents (III:3 and III:4) were genotyped by using the Illumina 720K SNP array 
(HumanOmniExpress Bead Chip by Illumina Inc®, San Diego, CA, USA) (Figure 1). PLINK(6) was 
used to analyze the genotyping data and to calculate the run of homozygosity (ROH). A ROH was 
defined as the region of 50 consecutive homozygous SNPs, allowing a maximum of one mismatch 
and bordered by the first heterozygous SNP at the edge.  
Molecular modeling of the SLC6A6 missense variant 
To predict the potential structural consequences of the SLC6A6 Gly399Val variant, the dopamine 
transporter structure with bound cocaine molecule (PDB 4xp4) template was used. The UCSF 
Chimera software(7) was used to model SLC6A6 protein with (Gly399Val) or without (Gly399) 
variants, and to visualize the resulting protein structures. 
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Cell and fibroblast Culture 
Human embryonic kidney (HEK-293) cell lines were transfected with standard TransIT-LT1 
protocol to stably express either wildtype taurine transporter SLC6A6 (formerly called TauT) or a 
SLC6A6 containing the SNP G399V. Cells and primary fibroblasts were maintained in Dulbecco's 
Modified Eagle's medium (DMEM), 10% Fetal Bovine Serum (FBS), 1% PSA Antibiotic solution 
(10,000 units of penicillin, 10,000 µg of streptomycin, and 25 µg of Amphotericin B per mL) at 
37˚C and 5% CO2 and were typically used for experiments after reaching 60%-70% confluency. 
 
[3H Taurine] Uptake Assay 
HEK-293 cells transiently transfected or stably expressing SLC6A6 or the G399V mutation 
(100,000 cells/well) or primary fibroblasts (50,000 cells/well) were plated in a 24 well culture 
plate (culturplate-24, Perkin-Elmer, Inc) and grown for 24 h. Cells were washed twice with 0.5 mL 
KR buffer (130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 10 mM 
HEPES, and 10 mM glucose, pH 7.4.) KR buffer of pH 5.5 was used to perform uptakes as SLC6A6 
is more active under acidic conditions. Single point uptake of 30 nM or 5 µM [3H] taurine (Perkin 
Elmer) with vehicle or indicated concentrations of cold taurine was carried out for 10 minutes at 
37˚C. 5 µM was obtained by mixing [3H] taurine with non-labeled taurine. Uptake was terminated 
with three washes of ice-cold KR buffer of pH 7.4. Radioactivity remaining in cells was measured 
by liquid scintillation. Non-specific uptake was determined for HEK-293 cells by subtracting 
radioactivity obtained with parental, non-transfected cells. Non-specific uptake for primary 
fibroblasts was determined by uptake in the presence of 25 mM non-labeled β-alanine. For 
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saturation analysis, [3H] taurine was diluted into non-labeled taurine to obtain the necessary 
concentrations. Uptake was performed for 10 min followed by wash with cold-KR. Non-specific 
counts were determined as above. Statistical significance was determined using unpaired T-Test 
and one-way ANOVA (post-Tukey Test) with significance set at p < 0.05. 
 
Surface Biotinylation 
HEK-293 cells stably expressing SLC6A6 and G399V mutation (100,000 cells/plate) or primary 
fibroblasts (100,000 cells/plate) were plated in a 100 mM culture plate. At 70% confluency, 
primary fibroblasts were treated with 50 mM NaCl (final concentration) to enhance SLC6A6 
expression. After 12-17 h incubation, all remaining steps were performed on ice to prevent 
trafficking. Surface SLC6A6 levels were isolated by treatment with 0.5 mg/mL Sulfo-NHS-SS-biotin 
(ThermoFisher, USA) for 25 minutes upon gentle shaking or rocking. Unreacted biotin was 
quenched by incubation with 100 mM glycine for 25 minutes with gentle rocking. Cells were 
solubilized with 500 µL RIPA buffer plus protease inhibitors for 15 minutes on ice. Lysed cells 
were spun for 20 minutes at 4˚C at 16,000 x g followed by collection of the supernatant. Cells 
were washed in between biotinylation, quenching and lysing twice with 1X Phosphate-buffered 
saline with Ca and Mg (PBS/CM) that contained (in mM): 137 mM NaCl, 2.7 mM KCl, 10.1 mM 
Na2HPO4, 1.8 mM KH2PO4, 0.1 mM CaCl2, 1.0 mM MgCl2, and 10 mM glucose, pH 7.4. 100 µg 
protein was reacted with 50% slurry neutrAvidin agarose beads (ThermoFisher) and rotated 
overnight at 4˚C. Beads are then pelleted at 300 x g for 2 minutes and washed with RIPA buffer 
three times. Beads are incubated with 2X loading dye for 30 minutes at 37˚C, followed by elution 
of proteins by pelleting the beads at 5,000 x g for 2 minutes. Purified proteins were resolved on 
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NEXTGEL® 10% acrylamide gels and transferred to 0.45 µM PVDF membranes (Immobilon-P, 
Millipore). Membranes were blocked for 2 hours at 5% bovine serum albumin (BSA) followed by 
incubation with SLC6A6 anti-rabbit polyclonal antibody (PA5-37460 Thermo Fisher Scientific) or 
chicken polyclonal anti-transferrin receptor (TFRC) primary antibody overnight at 4˚C. 
Membranes were incubated with HRP-conjugated goat anti-rabbit or goat anti-chicken 
secondary antibody for 1 hour at room temperature. Membranes were imaged on a LiCor C-Digit 
using WesternSure® PREMIUM Chemiluminescent Substrate (LiCor). SLC6A6 was normalized to 
TFRC for each membrane sample. Statistical significance was determined using one-way ANOVA 
(post-Tukey Test) with significance set at p < 0.05. 
 
Taurine loading test and supplementation 
A taurine loading test was performed in the Pediatrics clinical research unit of the University 
hospitals of Geneva after approval by the ethics committee. We have administered an oral bolus 
dose of 100mg/kg of Taurine to the two affected individuals and their heterozygous parents on 
day 2, this dose was recommended by the literature as non-toxic. Taurine was provided in tablets, 
commercialized by Burgerstein Pharmaceuticals. Repeated measurements of taurine in blood 
and urine were subsequently performed. On days 3 and 4, the patients received a 100mg/kg/day, 
administered in 3 doses (33mg/kg/q8hours). 
 
  




Genetic analyses reveal a missense variant in the taurine transporter SLC6A6 
The genetic analysis was initiated by performing exome sequencing of proband (IV:3) of family 
F315. More than 95% of the sequenced region was covered at 20x with a total mean coverage of 
~100x. An in-house pipeline and prioritization algorithm(4, 5) was used to analyze the high 
throughput sequencing data. None of the genes known to be implicated in retinal degeneration 
and all types of visual impairment has yielded any pathogenic variant. Then by combining the 
exome sequencing data of the proband and genotyping data of all family members, variants 
present in the regions of homozygosity (ROH) that segregated with the disease phenotype in 
recessive manner were selected and filtered as described previously(5, 8). By using this approach 
a homozygous missense variant (NM_003043.5:c.1196G>T:p.(Gly399Val) in SLC6A6 was 
identified (Figure 1). The variant SLC6A6:p.(Gly399Val) is not present in gnomAD, Bravo database 
(https://bravo.sph.umich.edu/freeze5/hg38/) or our local cohort of 300 controls from the same 
Pakistani ethnicity. As shown in the chromatograms (figure 1B), both the affected individuals 
(IV:1 and IV:3) are homozygous, both parents (III:3 and III:4) and one unaffected sibling (IV:4) are 
heterozygous for the variant (Gly399Val) and another unaffected sibling (IV:5) has both normal 
alleles; confirming the recessive inheritance of the variant. By sharing our findings through 
GeneMatcher(9), genetic conferences and meetings, we have not found any second case having 
pathogenic or likely pathogenic variants in the SLC6A6 gene. However, by publishing this article 
we hope to identify similar cases.  
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Clinical evaluation 
The two affected individuals and their parents were clinically evaluated at the University Hospital of 
Geneva. The results of the evaluation are described in the table 1. 
Figure S1. Fundus photographs and macular OCT (optical coherence tomography) before 
taurine supplementation 
 
Figure S1. Fundus photographs and macular OCT (optical coherence tomography) before taurine 
supplementation. (A) Fundus photographs of affected individuals (IV:1 and IV:3) of family F315. (B) 
OCT is normal in father (III:4) and mother (III:3), uniformly atrophic in affected boy (IV:1) and 
showing paracentral foveal-spearing photoreceptor atrophy in the affected girl (IV:3).  
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Plasma and urine amino acids and % kidney tubular reabsorption (tables S2 to S5) 
The tables below show the extremely low levels of taurine in the two affecteds (individuals IV:1 and 
IV:3) and intermediate levels for the carrier parents (individuals III:3 and III:4). A negative value for the 
renal tubular reabsorption of taurine was observed in the patients, while in the parents these 
reabsorption values were less than the normal controls. 
 











% renal tubular  
reabsorption 
Taurine 5 20 to 90 190 -60 
Threonine 72 31 to 30 14 99 
Serine 126 25 to 170 106 96 
Asparagine 48 - 11 99 
Glutamate 24 25 to 250 3 99 
Glutamine 607 60 to 470 81 99 
Proline 252 50 to 190 368 94 
Glycine 226 60 to 310 1182 78 
Alanine 228 100 to 310 27 100 
Citrulline 17 10 to 30 2 100 
Valine 142 60 to 260 5 100 
Cystine 28 25 to 65 8 99 
Methionine 20 5 to 30 0 100 
Isoleucine 45 25 to 95 2 100 
Leucine 78 45 to 155 3 100 
Tyrosine 45 10 to 120 12 99 
Phenylalanine 39 20 to 70 8 99 
Ornithine 33 10 to 110 1 100 
Lysine 117 45 to 145 11 100 
Histidine 66 25 to 110 57 96 
Arginine 78 10 to 65 2 100 
 











% renal tubular  
reabsorption 
Taurine 7 40 to 280 213 -110 
Threonine 165 100 to 190 14 99 
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Serine 194 70 to 160 54 98 
Asparagine 64  6 99 
Glutamate 24 25 to 90 2 99 
Glutamine 684 550 to 830 41 100 
Proline 507 100 to 380 2 100 
Glycine 396 150 to 320 90 98 
Alanine 408 240 to 600 19 100 
Citrulline 31 20 to 55 1 100 
Valine 202 180 to 325 4 100 
Cystine 36 40 to 75 7 99 
Methionine 31 20 to 45 1 100 
Isoleucine 70 50 to 120 1 100 
Leucine 115 105 to 215 2 100 
Tyrosine 63 40 to 100 9 99 
Phenylalanine 58 45 to 80 4 100 
Ornithine 41 30 to 100 1 100 
Lysine 167 135 to 260 11 100 
Histidine 75 65 to 110 46 96 
Arginine 109 35 to 140 1 100 
 










% renal tubular  
reabsorption 
Taurine 28 40 to 280 67 79 
Threonine 135 100 to 190 9 99 
Serine 102 70 to 160 36 97 
Asparagine 52  5 99 
Glutamate 27 25 to 90 1 100 
Glutamine 629 550 to 830 30 100 
Proline 389 100 to 380 1 100 
Glycine 296 150 to 320 229 93 
Alanine 489 240 to 600 22 100 
Citrulline 37 20 to 55 1 100 
Valine 216 180 to 325 2 100 
Cystine 49 40 to 75 7 99 
Methionine 28 20 to 45 0 100 
Isoleucine 75 50 to 120 1 100 
Leucine 127 105 to 215 1 100 
Tyrosine 71 40 to 100 7 99 
Phenylalanine 66 45 to 80 4 99 
Ornithine 58 30 to 100 1 100 
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Lysine 157 135 to 260 8 100 
Histidine 69 65 to 110 30 96 
Arginine 85 35 to 140 1 100 
 
 










% renal tubular  
reabsorption 
Taurine 31 30 to 55 87 83 
Threonine 197 75 to 235 20 99 
Serine 152 70 to 185 57 98 
Asparagine 62  9 99 
Glutamate 25 20 to 70 1 100 
Glutamine 607 440 to 810 49 100 
Proline 248 70 to 270 1 100 
Glycine 358 70 to 530 408 93 
Alanine 400 200 to 550 28 100 
Citrulline 38 15 to 55 1 100 
Valine 188 150 to 270 3 100 
Cystine 45 30 to 80 7 99 
Methionine 28 20 to 40 0 100 
Isoleucine 56 40 to 90 1 100 
Leucine 107 75 to 170 2 100 
Tyrosine 64 35 to 90 9 99 
Phenylalanine 57 40 to 70 7 99 
Ornithine 50 20 to 90 1 100 
Lysine 192 115 to 250 12 100 
Histidine 71 55 to 110 47 96 
Arginine 117 25 to 125 1 100 
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Functional analysis 
Functional analysis were performed to observe the effect of the SLC6A6 G399V variant on the taurine 
uptake and surface expression of the transporter(10).  
Figure S2. Taurine uptake in HEK-293 cells expressing the SLC6A6 G399V variant at high and 
low substrate concentrations 
  
 
Figure S2. Taurine uptake in HEK-293 cells expressing the SLC6A6 G399V variant at high and 
low substrate concentrations. HEK-MSR cells were transiently transfected with pcDNA3.1-
SLC6A6 or pcDNA3.1- SLC6A6 G399V and analyzed for taurine uptake for 25 min at 37˚C using 30 
nM and 5 µM [3H] taurine. Radioactivity incorporated into the cell was determined by 
scintillation counting and normalized to percent uptake by wild type SLC6A6. Background counts 
were determined from uptake in a non-transfected cell and were subtracted from test samples. 
N>3. Significance was determined by unpaired t-test. ***p<0.001. 
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Figure S3. Taurine Saturation Uptake Analysis of SLC6A6 G399V Mutant in HEK-293 Cells.  
 
Figure S3. Taurine Saturation Uptake Analysis of SLC6A6 G399V Mutant in HEK-293 Cells. HEK-
293 cells were transiently transfected with pcDNA3.1 containing SLC6A6 (filled square) or SLC6A6 
G399V (open square) and incubated with [3H]taurine concentrations from 0.05 to 100 µM for 10 
min. Endogenous SLC6A6 expression was subtracted using uptake values from non-transfected 
parental HEK-293 cells. 
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Table S6. Kinetic Analysis of Taurine uptake by SLC6A6 G399V Mutant 
 




SLC6A6 3.8 ± 0.31 30 ± 1.11 
SLC6A6 G399V 1.1 ± 0.05** 4.9 ± 0.24****  
  
Two-tailed unpaired t test, ** P<0.01, **** P<0.0001. 
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Figure S4. Taurine Uptake in Patient-derived Fibroblasts. 
 
Figure S4. Taurine Uptake in Patient-derived Fibroblasts. Percent uptake is plotted after 
normalization to IV:1. One-way ANOVA with Tukey’s multiple comparison post-hoc. All 
differences within fibroblast samples were significant at * p<0.05, *** p<0.001. Nonsignificant 
differences were indicated by ns. HEK-293 cells were used as a positive control as transfection 
with SLC6A6 plasmid shows significant ~12-fold increase in taurine transport over the 
endogenous SLC6A6 transport. 30 nM of [3H] taurine was used for the uptake analysis.  
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IV:1 15.5 ± 2.9 5.33 ± 0.36*** 
IV:3 15.0 ± 1.7 6.17 ± 0.79*** 
III:4 11.8 ± 3.5 12.3 ± 1.0### 
III:3 24.8 + 5.6 13.37 ± 0.95### 
 
One-way ANOVA with Tukey post hoc test.  *** P<0.001 significance from III:4 and III:3.  ###P<0.001 
significance from IV:1 and IV:3.  
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Figure S5. SLC6A6 Surface Expression from Transfected Tissue Culture Cells 
A       B 
 
 
SLC6A6 Surface Expression Analysis in Transiently Transfected HEK-293 Cells. (A) Western blot 
detection of SLC6A6 from purified plasma membrane biotinylated proteins extracted from 
parental HEK-293 cells (Par) and cells transiently transfected with 200 ng of plasmid DNA allowing 
expression of SLC6A6 or SLC6A6 G399V. Blots were striped and probed for the plasma membrane 
transferrin receptor which was used to normalize SLC6A6 expression. (B) Plot of densitometry 
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Taurine loading test 
A baseline profile of taurine levels in blood and urine was first measured in both affected children 
and their parents; serial measurements without taurine supplementation were obtained during 
day 1. The results showed extremely low levels of taurine in the two affected individuals (around 
5 µmol/l), while their heterozygous parents had intermediate levels. The standard daily diet did 
not increase the blood taurine levels in the patients or their parents (see Figure S9, day 1). 
The results were as follows (figure S9): 
• In the two affected children and their parents, blood taurine levels reached a high peak 
(400-900 µmol/l) after 4 hours; after 8 hours, the levels were still elevated (> 100 µmol/l). 
• The kinetics of blood taurine levels were similar between the patients and their parents. 
Moreover, the time of the peak of blood Taurine levels after the bolus administration was 
comparable to that of normal volunteers. 
• On days 3 and 4, we observed that the taurine supplementation 3 times a day in the 
affecteds, resulted in a peak of around 250 µmol/l. More importantly, even though the 
last administration of taurine was at 8pm, the fasting levels in the next morning were 
between 53 and 78 µmol/l, which correspond to the usual heterozygous levels without 
supplementation or the low normal range. 
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Figure S6. Taurine loading test.  
 
Figure S6. Taurine loading test. Blood Taurine levels in the 4 members of the family, before and 
after the Taurine loading test, and the Taurine supplementation, performed at the University 
Hospitals of Geneva. For discussion of the results see text. 
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Figure S7. Plasma taurine levels in healthy volunteers. 
 
Figure S7. Plasma taurine levels in healthy volunteers. Linear plot of mean plasma taurine levels 
(mmoL) in eight healthy volunteers following administration of 4 g (32 mmoL) oral taurine (this 
dose is about half of that used in the members of the F315 family). Data from Ghandforoush-
Sattari M et al(11). 
These results show that daily supplementation of taurine is sufficient to increase taurine to low 
normal blood levels: thus, since the mutation in these patients allows a 10-18% intracellular 
transport of taurine, the increased levels in blood could provide sufficient taurine transport in 
the retina cells and prevent further destruction of photoreceptors in the affected female. 
Moreover, this supplementation could avoid progression of the cardiomyopathy in both affected 
children. 
Taurine supplementation and 2 year follow up 
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Figure S8. Fundus photographs and OCT of boy (IV:1) after two years of taurine 
supplementation. 
 
Figure S8. Fundus photographs and OCT of boy (IV:1) after two years of taurine supplementation. 
(A) Fundus photographs (A) and OCT (B) of the affected individual (IV:1) of family F315. Results show 
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Figure S9. Fundus photographs and OCT of the affected girl (IV:3) before the taurine 
supplementation. Fundus photographs and OCT of affected girl (IV:3) of family F315 show a 
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Figure S10. Fundus photographs and OCT of the affected girl (IV:3) 1-year after the taurine 
supplementation.  
 
Figure S10. Fundus photographs and OCT of the affected girl (IV:3) 1-year after the taurine 
supplementation. Fundus photographs and OCT of affected girl (IV:3) show the anatomical stability 
with preservation of foveal photoreceptors. 
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Figure S11. Fundus photographs and OCT of the affected girl (IV:3) 2-year after the taurine 
supplementation.  
 
Figure S11. Fundus photographs and OCT of the affected girl (IV:3) 2-year after the taurine 
supplementation. Fundus photographs and OCT of affected girl (IV:3) show the anatomical stability 
with preservation of foveal photoreceptors. Her brother (IV:1) had complete visual loss at this age. 
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                    Normal                                        Before treatment                     1-year of taurine suppl.            2-years of taurine suppl. 








Figure S12. Multifocal ERG before and after one and two-years of taurine supplementation. 
Multifocal ERG of the patient (IV:3) showing diminished but residual response in the macular 
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Table S1: Clinical features of affected individuals with recessive SLC6A6 variants. 
 
  15 y.o individual IV:1 of fig 1 6 y.o. individual IV:3 of fig 1 
General Height 169cm (+0.5 SD) 
Weight 48.5kg (-1 SD) 
HC 51.5cm (-3 SD) 
  
Pectus carinatum 
No dysmorphic features 
Height 107cm (-1.5 SD) 
Weight (-2 SD) 
HC 46.5cm (-3.5 SD) 
  
  
No dysmorphic features 
Neurology Cranial nerves: normal 
Muscle tone and strength: normal 
Reflexes: normal 
Cerebellar exam: normal 
  
Brain MRI: normal 
Cranial nerves: normal 
Muscle tone and strength: normal 
Reflexes: normal 
Cerebellar exam: normal 
  
Brain MRI: normal 
ENT Bilateral scars on tympanic membranes 
  
Audiometry: normal 
Bilateral seromucous otitis 
  
Audiometry: slight decrease (10-20 dB) in low 
frequencies, of conductive origin 
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Cardiology BP: 127/70 mmHg 
Heart rate: 102/min 
Saturation: 100% AA 
  
No heart murmurs 
  
Echocardiography: mild hypokinetic cardiomyopathy 
with systolic dysfunction (shortening fraction 26-27 %) 
and slight systolic dilatation of left ventricle (Z score 
+3.2). 
  
Effort test: normal 
BP: 103/73 mmHg 
Heart rate: 135/min 
Saturation: 100% AA 
  
No heart murmurs 
  
Echocardiography: mild hypokinetic cardiomyopathy 
with systolic dysfunction (shortening fraction 24 %) 
and slight systolic dilatation of left ventricle (Z score 
+2.5). 
  
 Effort test: normal 
Ophthalmology Visual acuity: Light perception ODS 
  
Fundus: advanced cone-rod dystrophy, severe 
peripheral alterations and central atrophy 
 
Autofluorescence: severe peripheral and central 
hypoautofluorescence with a preserved paracentral 
ring of isoautofluorescence 
  
Global electroretinogram (ERG): extinguished 
 
Multifocal ERG: not possible to perform due to 
complete visual loss 
  
 
Visual field: not possible to perform 
  
Visual acuity: Counting fingers ODS 
  
Fundus: cone-rod dystrophy, salt-and-peper 
peripheral alterations and paracentral macular 
atrophy 
 
Autofluorescence: central area of isoautofluorescence 
with a ring of hypoautofluorescence and outer ring of 
hyperautofluorescence; normal autofluorescence in 
retinal periphery 
 
Global electroretinogramm (ERG): extinguished 
 
Multifocal ERG: minimal foveal macular response 
  
Visual field: abnormal, paracentral scotoma with a 
relatively preserved peripheral visual field 
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Optic coherence tomography (OCT): extended atrophy 
of the retina predominantly in the outer layers 
  
Optic coherence tomography (OCT): parafoveal outer 
retinal and photoreceptor atrophy; preservation of 
foveal photoreceptors 
Hepatic Transaminases, γGT, bilirubin, PA, albumin and 
coagulation studies: normal 
  
Abdominal ultrasound with ARFI: normal; no evidence 
of hepatic fibrosis 
Transaminases, γGT, bilirubin, PA, albumin and 
coagulation studies: normal 
  
Abdominal ultrasound with ARFI: normal; no evidence 
of hepatic fibrosis 
Biochemical 
testing 
Very low levels of blood taurine 
Markedly increase of urinary taurine levels 
Very low levels of blood taurine 
Markedly increase of urinary taurine levels 
  
 
 
